Format

Send to

Choose Destination
Cancer Cell. 2010 Dec 14;18(6):548-51. doi: 10.1016/j.ccr.2010.11.033.

ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.

Author information

1
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, 75390, USA. david.gerber@utsouthwestern.edu

Abstract

It was only 3 years ago that an acquired translocation of EML4 with ALK leading to the expression of an EML4-ALK oncoprotein in non-small cell lung cancer (NSCLC) was reported. Tumor cells expressing EML4-ALK are "addicted" to its continued function. Now, crizotinib, an oral ALK inhibitor, is demonstrated to provide dramatic clinical benefit with little toxicity in patients having such advanced NSCLC, and a mechanism of clinical resistance to crizotinib is identified. Such therapy "targeted" at oncogenic proteins provides "personalized" medicine and prompts genome-wide mutation analysis of human tumors to find other therapeutic targets.

PMID:
21156280
PMCID:
PMC3110762
DOI:
10.1016/j.ccr.2010.11.033
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center